Clinical Trial Update: Gemcitabine and ISIS 2503 in Treating Patients With Advanced or Metastatic Cancer of the Pancreas [Phase 2]

View source ↗

Summary

Phase 2 trial update of Gemcitabine plus ISIS 2503 in advanced pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• ISIS 2503 (ISIS-2503)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Pancreatic Cancer | Phase 2 | Status: COMPLETED